贝康医疗-B(02170)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02170 贝康医疗-B

交易中 05-21 14:20:33

1.580

+0.020

+1.28%

最高1.580	最低1.550	成交量11.10万
今开1.560	昨收1.560	日振幅1.92%
总市值4.32亿	流通市值1.31亿	总股本2.74亿
成交额17.26万	换手率0.13%	流通股本8,271万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02170","market":"HK","secType":"STK","nameCN":"贝康医疗-B","latestPrice":1.58,"timestamp":1779344421110,"preClose":1.56,"halted":0,"volume":111000,"delay":0,"changeRate":0.012820512820512832,"floatShares":82713835,"shares":273526000,"eps":-0.816942,"marketStatus":"交易中","change":0.02,"latestTime":"05-21 14:20:33","open":1.56,"high":1.58,"low":1.55,"amount":172635,"amplitude":0.019231,"askPrice":1.64,"askSize":19500,"bidPrice":1.58,"bidSize":6000,"shortable":0,"etf":0,"ttmEps":-0.909101,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1779351000000},"marketStatusCode":2,"adr":0,"listingDate":1612713600000,"exchange":"SEHK","adjPreClose":1.56,"openAndCloseTimeList":[[1779327000000,1779336000000],[1779339600000,1779350400000]],"volumeRatio":0.514008,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02170","defaultTab":"news","newsList":[{"id":"2635789775","title":"贝康医疗-B(02170)：Gems卵裂胚培养液获国家药监局颁发三类医疗器械证","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789775","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635789775?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:29","pubTimestamp":1778671793,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B 发布公告，公司自主研发的Gems卵裂胚培养液于近日成功获批国家三类医疗器械注册证。在此次获批之前，Gems卵裂胚培养液已分别取得欧洲合格认证、 美 国食品药品监督管理局认证及澳大利亚药品管理局认证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441354.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1100","09996","BK1222","BK1574","BK1597","159883","02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181129719","title":"贝康医疗-B 获得NMPA三类医疗器械注册证 其胚胎培养液产品获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1181129719","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181129719?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:27","pubTimestamp":1778671638,"startTime":"0","endTime":"0","summary":"苏州贝康医疗股份有限公司近日宣布，其研发的Gems Cleavage胚胎培养液产品，已成功获得国家药品监督管理局颁发的三类医疗器械注册证。\n此次获批标志着该产品获准在中国市场正式上市销售，为公司辅助生殖产品线增添了重要的核心产品。三类医疗器械是监管级别最高的医疗器械，通常用于支持或维持生命，其注册审批过程严格且复杂。\n该胚胎培养液主要用于辅助生殖技术中的胚胎体外培养环节，是胚胎发育过程中的关键耗材。此次获批有望进一步巩固贝康医疗在辅助生殖领域的市场地位，并为其未来业绩增长提供新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1597","BK1574","02170","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219560","title":"贝康医疗-B(02170)拟实施H股全流通计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219560","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634219560?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:09","pubTimestamp":1778587773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B(02170)公布，董事会已审议及批准建议实施H股全流通，以转换合共约1.91亿股公司未上市股份为公司H股。待取得所有相关批准及╱或备案(包括中国证监会的备案通知及联交所的批准)并符合所有适用法律、法规及规则后，该等未上市股份将转换为H股，且公司将申请批准该等H股于联交所主板上市及买卖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02170","BK1222","BK1597","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125751121","title":"贝康医疗-B发布2026年4月股份变动月报，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1125751121","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125751121?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:49","pubTimestamp":1778057346,"startTime":"0","endTime":"0","summary":"苏州贝康医疗股份有限公司于2026年5月6日发布截至2026年4月30日的证券变动月报表。本月公司注册股本与已发行股份总数均未发生变化。报告显示，截至4月末，公司股本总额为人民币273,526,000元，每股面值人民币1元。公司明确指出，自2026年1月1日起，未回购任何上市证券。公司表示将继续严格遵守香港联交所《上市规则》及其他相关法律法规的规定，并将按时披露后续的股份变动信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8d4c202617d87be1d9fe31f833a300a8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163529632","title":"贝康医疗-B获PGT-M试剂盒三类医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=1163529632","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163529632?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:11","pubTimestamp":1777464677,"startTime":"0","endTime":"0","summary":"苏州贝康医疗股份有限公司宣布，其PGT-M试剂盒已成功获得国家药品监督管理局颁发的三类医疗器械注册证书。这一重要资质的取得，标志着该产品获准在中国市场正式上市销售与应用。\n三类医疗器械注册证是医疗器械监管体系中的最高级别认证，通常适用于具有较高风险、需要采取特别措施严格控制管理以保证其安全有效的医疗器械。此次获批的PGT-M试剂盒将主要用于胚胎植入前遗传学检测，有助于提升辅助生殖领域的精准诊断水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170","BK1222","BK1574","BK1597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631251557","title":"贝康医疗-B(02170)：PGT-M试剂盒获国家药监局颁发三类医疗器械证","url":"https://stock-news.laohu8.com/highlight/detail?id=2631251557","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631251557?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:40","pubTimestamp":1777462801,"startTime":"0","endTime":"0","summary":"本次获批的PGT-M试剂盒是国内首个针对地中海贫血家系遗传阻断的PGT-M产品，填补了我国单基因病胚胎植入前遗传学检测领域的国产空白。随着PGT-M试剂盒获批上市，集团的产品线进一步丰富，将有效带动遗传实验室业务收入增长，有望成为公司未来业绩增长的重要驱动力，并进一步巩固集团在中国三代试管婴儿基因检测试剂盒市场的领导地位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1100","09997","09996","BK1222","BK1574","BK1597","159883","02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128359768","title":"贝康医疗-B（02170）2025年度业绩：收入2.33亿元 毛利率升至53%，年内亏损小幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1128359768","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128359768?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:54","pubTimestamp":1776848062,"startTime":"0","endTime":"0","summary":"贝康医疗-B公布截至2025年12月31日止年度的经营及财务表现。财务数据显示，公司全年收入为2.33亿元人民币，较2024年的2.99亿元同比下降22.0%；毛利达1.24亿元，较上年度1.36亿元下降9.3%，同时毛利率由45.5%上升至53.0%。年内亏损为2.23亿元，较2024年的2.37亿元有所收窄，亏损幅度减少约5.8%。展望后续阶段，贝康医疗-B将继续深化“IVD至IVF”平台布局，聚焦生殖诊断和辅助生殖器械的研发与市场推广，并通过海外合作与本地化生产提升供应链效能。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"贝康医疗-B（02170）2025年度业绩：收入2.33亿元 毛利率升至53%，年内亏损小幅收窄","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148406290","title":"贝康医疗-B发布3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1148406290","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148406290?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:43","pubTimestamp":1775724230,"startTime":"0","endTime":"0","summary":"苏州贝康医疗股份有限公司于2026年4月9日披露3月股份变动月报表，报告期截至2026年3月31日。根据公告，报告期内公司已发行股本结构保持不变，未发生新增发行、购回、注销或库藏股变动。根据月报，本月底法定/注册股本总额人民币273,526,000元。其中，H股已发行股份为82,713,835股，内资股为183,181,817股，未上市外资股为7,630,348股。上述各类股份数均与上月底保持一致，期内未见任何增减变动。本次公告由执行董事梁波签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625937512","title":"贝康医疗-B(02170)：受精培养液和囊胚培养液获国家药监局颁发医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937512","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625937512?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:29","pubTimestamp":1775561354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B 发布公告，本公司Gems系列两款核心培养液产品 — 受精培养液和囊胚培养液于2026年4月2日双双获得国家药品监督管理局颁发的三类医疗器械注册证。此次获证的受精培养液与囊胚培养液，与今年2月已获批的Geri胚胎培养液、 2025年获批的胚胎处理液，共同构成了覆盖“受精→卵裂胚培养→囊胚培养”全流程的Gems全品系培养液矩阵。受精培养液专为卵母细胞和精子提供适宜的受精环境，以促进受精。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02170","BK1574","09996","BK1597","BK1222","BK1583","BK1100","159883","09997"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125689831","title":"贝康医疗-B(02170.HK) 受精培养基与囊胚培养基获国家药监局医疗器械注册证批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1125689831","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125689831?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:44","pubTimestamp":1775558662,"startTime":"0","endTime":"0","summary":"苏州贝康医疗宣布，其两款核心产品——受精培养基与囊胚培养基，已正式获得国家药品监督管理局（NMPA）颁发的医疗器械注册证书。此次获批标志着公司在辅助生殖领域的研发实力与产品商业化进程取得重要突破，相关产品将有望进一步服务于国内生殖医学临床需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170","BK1222","BK1574","BK1597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624639548","title":"贝康医疗：受精+囊胚培养液双双获证，辅助生殖国产替代迎来“王者回归”","url":"https://stock-news.laohu8.com/highlight/detail?id=2624639548","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624639548?lang=zh_cn&edition=full","pubTime":"2026-04-03 09:37","pubTimestamp":1775180261,"startTime":"0","endTime":"0","summary":"当第一个拥有大规模临床试验数据的中国本土全品系培养液品牌强势归来，当国产替代从“概念”变为“现实”，贝康医疗无疑正处于价值发现的关键节点。","market":"sg","thumbnail":"https://img2.gelonghui.com/b17e2-5ff0c5e8-60db-45ba-8e64-4b183caf021d.jpg?guru_height=720&guru_width=1280&guru_size=154189","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b17e2-5ff0c5e8-60db-45ba-8e64-4b183caf021d.jpg?guru_height=720&guru_width=1280&guru_size=154189"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4291618","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1597","BK1222","02170","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623377568","title":"贝康医疗2025业绩亮点：从IVD到IVF全场景AI平台，成为中国辅助生殖领域行业龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2623377568","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623377568?lang=zh_cn&edition=full","pubTime":"2026-03-31 12:49","pubTimestamp":1774932592,"startTime":"0","endTime":"0","summary":"伴随国产智造与人工智能的双重浪潮，贝康医疗正以确定的盈利预期和坚实的竞争壁垒，叩响辅助生殖赛道价值重估的大门。","market":"fut","thumbnail":"https://img2.gelonghui.com/b17e2-5257232d-3843-4fee-aee1-cf4340bf53a5.jpg?guru_height=720&guru_width=1280&guru_size=154189","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b17e2-5257232d-3843-4fee-aee1-cf4340bf53a5.jpg?guru_height=720&guru_width=1280&guru_size=154189"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4247094","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1222","BK1597","BK4082","BK1574","AIPO","02170","AGIX","CHAT","IVF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623328501","title":"贝康医疗-B(02170)发布年度业绩，收入2.33亿元 核心产品注册、国产化推进及平台型业务布局方面取得多项重要进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2623328501","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623328501?lang=zh_cn&edition=full","pubTime":"2026-03-31 01:24","pubTimestamp":1774891440,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B 发布截至2025年12月31日止年度业绩，该集团取得收入2.33亿元，同比减少22.01%;公司权益股东应占亏损2.23亿元，同比减少5.7%;每股亏损0.8元。2025年，对本集团而言，是由“研发及注册驱动”逐步迈向“商业化落地及经营优化驱动”的关键一年。报告期内，本集团在核心产品注册、国产化推进及平台型业务布局方面取得多项重要进展。于男科领域，家用精子检测设备获批上市，进一步完善本集团在辅助生殖前端检测场景的产品布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"贝康医疗-B(02170)发布年度业绩，收入2.33亿元 核心产品注册、国产化推进及平台型业务布局方面取得多项重要进展","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02170","BK1222","BK1597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164550073","title":"贝康医疗-BPGT-A检测试剂盒获中国药监局三类医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=1164550073","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164550073?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:35","pubTimestamp":1773664549,"startTime":"0","endTime":"0","summary":"贝康医疗-B（股票代码：02170）近日宣布，其自主研发的PGT-A检测试剂盒已正式获得中国国家药品监督管理局（NMPA）颁发的三类医疗器械注册证。这一重要进展标志着该产品在中国市场合规上市的关键一步，有望为辅助生殖领域提供更精准、可靠的检测工具。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02170","BK1222","BK1597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619045006","title":"贝康医疗-B(02170)：PGT-A试剂盒获国家药监局颁发医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2619045006","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619045006?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:05","pubTimestamp":1773662722,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B 公布，公司基于国产高通量基因测序平台的 PGT-A试剂盒，胚胎植入前染色体非整倍体检测试剂盒，于2026年3月13日成功获批国家三类医疗器械注册证，成为全国首个基于纯国产自主平台测序仪的PGT-A试剂盒。PGT-A试剂盒透过筛检胚胎染色体非整倍体异常，能有效降低流产风险和出生缺陷发生率，是第三代试管婴儿技术的关键支撑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02170","BK1597","159883","09996","BK1222","BK1100","BK1574","09997","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618999172","title":"贝康医疗-B03月10日主力净流入18.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2618999172","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618999172?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:15","pubTimestamp":1773130544,"startTime":"0","endTime":"0","summary":"03月10日, 贝康医疗-B股价涨7.57%，报收1.99元，成交金额28.8万元，换手率0.18%，振幅8.11%，量比2.14。贝康医疗-B今日主力资金净流入18.8万元，上一交易日主力净流出0万元。该股近5个交易日上涨9.94%，主力资金累计净流入36.6万元；近20日主力资金累计净流入62.1万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310161854a6b4c7b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310161854a6b4c7b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02170","BK1222","BK1597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128578366","title":"贝康医疗-B（02170）2026年2月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1128578366","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128578366?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:42","pubTimestamp":1772617374,"startTime":"0","endTime":"0","summary":"贝康医疗-B（02170）于2026年3月4日披露2026年2月证券变动月报表。报告显示，截至2026年2月28日，公司已发行股本及注册股本维持不变，未发生新增发行、购回或注销股份等变动。\n苏州贝康医疗股份有限公司目前拥有普通股合计273,526,000股（面值每股人民币1元）。其中，H股为82,713,835股，内资股为183,181,817股，未上市外资股为7,630,348股，均与上月末保持一致，库藏股数量也为零。\n公司说明已符合香港联交所对最低公众持股量的相关要求，并确认遵守《上市规则》及其他适用法规。本次公告由执行董事梁波签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614501758","title":"贝康医疗-B(02170)：Geri胚胎培养液(Gems胚胎培养液系列产品之一)获国家药监局颁发医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2614501758","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614501758?lang=zh_cn&edition=full","pubTime":"2026-02-26 18:51","pubTimestamp":1772103109,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B 发布公告，本公司的Geri胚胎培养液于2026年2月25日获得中国国家药品监督管理局颁发的三类医疗器械注册证。结合Geri湿式时差培养箱与AI胚胎评估系统，Geri胚胎培养液已正式进入中国临床实践，以其抗氧化配方与稳定渗透压环境的两大核心优势，解决了高龄患者胚胎培养的难题。Geri胚胎培养液的技术核心在于针对高龄患者生育难点构建系统性解决方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1222","02170","BK1574","BK1100","159883","09996","09997","BK1597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613013785","title":"贝康医疗-B02月23日主力净流入11.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2613013785","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613013785?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:15","pubTimestamp":1771834553,"startTime":"0","endTime":"0","summary":"02月23日, 贝康医疗-B股价涨3.87%，报收1.88元，成交金额64.7万元，换手率0.43%，振幅3.31%，量比1.77。贝康医疗-B今日主力资金净流入11.6万元，上一交易日主力净流出0万元。该股近5个交易日下跌2.08%，主力资金累计净流入25.4万元；近20日主力资金累计净流出6.4万元，其中净流出天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223162000a4be73dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223162000a4be73dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1597","02170","BK1222","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143494261","title":"苏州贝康医疗（02170）2026年1月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1143494261","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143494261?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:06","pubTimestamp":1770196001,"startTime":"0","endTime":"0","summary":"苏州贝康医疗股份有限公司于2026年2月4日发布2026年1月股份变动月报表，披露截至2026年1月31日的股本结构及变动情况。公司目前注册及已发行股本包括：H股82,713,835股、内资股183,181,817股以及未上市外资股7,630,348股，各类股份自上月以来均未出现新增发行或购回注销情况，总股本维持在273,526,000股。公司表示已遵守香港联交所《上市规则》的相关规定要求，确认截至2026年1月31日的H股公众持股量满足上市规则标准。本次月报表由执行董事梁波签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.1381},{"period":"1month","weight":-0.1917},{"period":"3month","weight":-0.1522},{"period":"6month","weight":-0.2571},{"period":"1year","weight":-0.4676},{"period":"ytd","weight":-0.1613}],"compareEarnings":[{"period":"1week","weight":-0.0279},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0395},{"period":"6month","weight":0.0171},{"period":"1year","weight":0.0832},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州贝康医疗股份有限公司（原名：江苏双螺旋生物科技有限公司）是一家主要提供辅助生殖基因检测解决方案的中国投资控股公司。该公司提供基因检测解决方案及销售基因检测设备及仪器。基因检测解决方案包括销售检测试剂盒及提供检测服务。该公司主要产品包括PGT-A试剂盒。该公司主要于国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.002951},{"month":2,"riseRate":0.6,"avgChangeRate":0.105265},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.100603},{"month":4,"riseRate":0.5,"avgChangeRate":0.007862},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.090294},{"month":6,"riseRate":0.2,"avgChangeRate":-0.028295},{"month":7,"riseRate":0.4,"avgChangeRate":-0.049384},{"month":8,"riseRate":0.4,"avgChangeRate":-0.045091},{"month":9,"riseRate":0.4,"avgChangeRate":-0.013645},{"month":10,"riseRate":0.4,"avgChangeRate":0.015037},{"month":11,"riseRate":0.2,"avgChangeRate":-0.017242},{"month":12,"riseRate":0.2,"avgChangeRate":-0.11073}],"exchange":"SEHK","name":"贝康医疗-B","nameEN":"BASECARE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝康医疗-B(02170)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝康医疗-B(02170)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝康医疗-B,02170,贝康医疗-B股票,贝康医疗-B股票老虎,贝康医疗-B股票老虎国际,贝康医疗-B行情,贝康医疗-B股票行情,贝康医疗-B股价,贝康医疗-B股市,贝康医疗-B股票价格,贝康医疗-B股票交易,贝康医疗-B股票购买,贝康医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝康医疗-B(02170)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝康医疗-B(02170)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}